prasterone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
androgens/anabolic steroids 795 53-43-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • intrarosa
  • 5,6-didehydroepiandrosterone
  • androstenolone
  • dehydroandrosterone
  • dehydroepiandrosterone
  • dehydroisoandrosterone
  • prasterone
A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
  • Molecular weight: 288.43
  • Formula: C19H28O2
  • CLOGP: 3.07
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 37.30
  • ALOGS: -3.82
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
6.50 mg V

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
None FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Butterfly rash 134.12 19.69 27 2825 1209 50601063
Periorbital oedema 96.53 19.69 27 2825 4985 50597287
Photosensitivity reaction 78.74 19.69 29 2823 12882 50589390
Head discomfort 68.11 19.69 25 2827 10994 50591278
Off label use 67.86 19.69 106 2746 474320 50127952
Swelling face 57.05 19.69 36 2816 52559 50549713
Tinnitus 57.00 19.69 29 2823 28103 50574169
Feeling hot 50.60 19.69 30 2822 39172 50563100
Application site discharge 46.13 19.69 8 2844 156 50602116
Hypothalamic pituitary adrenal axis suppression 33.29 19.69 6 2846 147 50602125
Cellulitis 32.62 19.69 29 2823 70769 50531503
Therapeutic response unexpected 31.04 19.69 16 2836 15899 50586373
Vaginal discharge 29.11 19.69 11 2841 5229 50597043
Dehydroepiandrosterone increased 26.35 19.69 3 2849 0 50602272
Headache 24.44 19.69 73 2779 506462 50095810
Granulomatous liver disease 23.84 19.69 6 2846 737 50601535
Adrenocortical insufficiency acute 19.89 19.69 6 2846 1438 50600834

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tendon calcification 37.36 29.28 5 550 51 29573921
Progesterone increased 34.83 29.28 4 551 9 29573963

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Butterfly rash 146.05 22.46 27 2416 1155 64495134
Periorbital oedema 96.71 22.46 27 2416 7387 64488902
Photosensitivity reaction 76.60 22.46 28 2415 18145 64478144
Head discomfort 76.11 22.46 25 2418 11809 64484480
Tinnitus 65.79 22.46 30 2413 34103 64462186
Swelling face 58.19 22.46 33 2410 59133 64437156
Feeling hot 57.49 22.46 30 2413 45633 64450656
Cellulitis 42.10 22.46 32 2411 93625 64402664
Off label use 37.42 22.46 77 2366 632729 63863560
Tendon calcification 29.59 22.46 5 2438 126 64496163
Application site discharge 25.35 22.46 5 2438 301 64495988
Headache 25.04 22.46 59 2384 529408 63966881
Dehydroepiandrosterone increased 24.60 22.46 3 2440 5 64496284
Granulomatous liver disease 23.24 22.46 6 2437 1216 64495073

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A14AA07 ALIMENTARY TRACT AND METABOLISM
ANABOLIC AGENTS FOR SYSTEMIC USE
ANABOLIC STEROIDS
Androstan derivatives
ATC G03EA03 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
ANDROGENS AND FEMALE SEX HORMONES IN COMBINATION
Androgens and estrogens
ATC G03XX01 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Other sex hormones and modulators of the genital system
MeSH PA D000276 Adjuvants, Immunologic
MeSH PA D007155 Immunologic Factors
CHEBI has role CHEBI:50113 androgene
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Systemic lupus erythematosus indication 55464009 DOID:9074
Dyspareunia indication 71315007




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
6.5MG INTRAROSA MILLICENT N208470 Nov. 16, 2016 RX INSERT VAGINAL 8957054 Jan. 8, 2030 INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Corticosteroid-binding globulin Secreted Ki 5 CHEMBL
Sex hormone-binding globulin Secreted Kd 7.84 CHEMBL
Glucose-6-phosphate 1-dehydrogenase Enzyme Ki 5.21 CHEMBL
Beta-glucuronidase Enzyme IC50 4.11 CHEMBL
Glucose-6-phosphate 1-dehydrogenase Enzyme Ki 5.96 CHEMBL

External reference:

IDSource
4021360 VUID
N0000148779 NUI
D08409 KEGG_DRUG
1927689 RXNORM
4021360 VANDF
4036745 VANDF
CHEBI:28689 CHEBI
AND PDB_CHEM_ID
CHEMBL90593 ChEMBL_ID
2370 IUPHAR_LIGAND_ID
2869 INN_ID
DB01708 DRUGBANK_ID
459AG36T1B UNII
5881 PUBCHEM_CID
131731 MMSL
20676 MMSL
247058 MMSL
32118 MMSL
73034 MMSL
d04425 MMSL
004609 NDDF
413963008 SNOMEDCT_US
78316004 SNOMEDCT_US
D003687 MESH_DESCRIPTOR_UI
C0011185 UMLSCUI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 64011-601 INSERT 6.50 mg VAGINAL NDA 17 sections
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 72495-401 INSERT 6.50 mg VAGINAL NDA 17 sections
Intrarosa HUMAN PRESCRIPTION DRUG LABEL 1 72495-501 INSERT 6.50 mg VAGINAL NDA 17 sections
Debaochun HUMAN OTC DRUG LABEL 7 82570-016 POWDER 10 g TOPICAL unapproved drug other 8 sections